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Lymphovascular invasion (LVI) is strongly related to breast cancer (BC) metastasis. 
However, the underlying mechanisms of LVI and its driver molecules in BC remain to 
be defined. In this study, we explore differential expression of genes in large 
molecularly characterized and clinically annotated datasets of invasive BC patients 
(n=8056) coupled with histological review and strict definition for LVI status. The 
METABRIC series was used to identify genes associated with LVI, as defined using 
H&E supplemented by immunohistochemistry (IHC), at the genomic/transcriptomic 
levels. Saccharomyces cerevisiae-like 1 (SEC14L1) was identified as one of the 
most significant genes associated with LVI. The prognostic significance of SEC14L1 
gene copy number and mRNA expression was further investigated in the METABRIC 
series and externally validated using the Breast Cancer Gene-Expression Miner 
v4.0. Protein expression of SEC14L1 was also assessed using IHC in series of early 
stage BC using tissue microarrays. SEC14L1 gene copy number gain was 
significantly associated with high histological grade and poor outcome. SEC14L1 
mRNA expression showed positive association with higher grade, lymph node 
metastasis and poor outcome. SEC14L1 protein overexpression was significantly 
associated with LVI (p<0.0001), higher grade (p=0.011), HER2 positivity (p=0.036), 
and shorter survival (p=0.00075). Our findings specify SEC14L1 as an independent 
prognostic factor in BC. Its association, at both transcriptome and protein expression 
levels, with LVI and outcome could imply an important role in tumor progression. A 
further mechanistic insight into its molecular roles including potential therapeutic 
utility is warranted. 
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Although several biomarkers associated with breast cancer progression and 
response to therapy have been identified, the exact molecular signatures for invasion 
machineries that lead to metastatic disease remains to be defined. Deciphering the 
driver genes/proteins that dictate the biological metastatic behavior of breast cancer 
is essential to understanding cancer progressive mechanisms and opening novel 
avenues for therapeutic interventions. Lymphovascular invasion (LVI) is an 
independent prognostic parameter of poor outcome in invasive breast cancer and is 
major prerequisite for the development of metastasis (1-3). Comprehension of the 
molecular mechanisms underlying LVI in breast cancer and unveiling its key-players 
could lead to unique therapeutic targets and improve risk prediction (4-6). However, 
the sophistication of the molecular mechanisms underlying LVI as part of the 
invasion-metastasis cascade with involvement of several genes, diverse signaling 
pathways and interactions of tumor microenvironment in addition to the subjectivity 
of LVI morphological assessment in clinical samples renders this task highly 
challenging (6). 
Advancement in high-throughput molecular and bioinformatics techniques coupled 
with thorough pathological assessment could help decipher LVI molecular regulators 
in breast cancer. Therefore, we have interrogated transcriptomic profiles of the large-
scale cohort of invasive breast cancer patients of the METABRIC following 
morphological and molecular assessment for LVI status to identify LVI differentially 
expressed genes [7]. Cytosolic factor Saccharomyces cerevisiae-like 1 (SEC14L1) 
was identified as one of the most significant genes associated with LVI using 
genomic data. 
The aim of the present study was to evaluate the clinicopathological and prognostic 
significance of SEC14L1 copy number alteration (CNA) and mRNA expression in the 
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large annotated cohort of the METABRIC. Associations of SEC14L1 protein 
expression with clinicopathological prognostic variables including LVI, intrinsic 
molecular subtypes, and patient outcome were assessed. Our interpretation of the 
prognostic impact of SEC14L1 expression in invasive BC patients may unveil new 
insights on the sophisticated pathways of LVI. 
 
MATERIAL AND METHODS 
Analysis of differential gene expression  
The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) 
cohort [8, 9] is a large genomic and transcriptomic dataset from 1980 primary 
operable invasive BC female patients. In this cohort, the ER-positive and/or lymph 
node metastasis negative patients were treated without adjuvant chemotherapy. The 
ER-negative or lymph node positive patients had adjuvant chemotherapy. No HER2-
positive breast cancer patients had trastuzumab therapy. The extracted and purified 
DNA probes were hybridized to Affymetrix SNP 6.0 arrays (Affymetrix, Santa Clara, 
CA) at AROS Applied Biotechnology (Aarhus, Denmark). For RNA analysis, the 
Illumina Totalprep RNA amplification kit and Illumina Human HT-12 v3 Expression 
BeadChips (Ambion, Warrington, UK) were used as described previously [8]. 
We interrogated the Nottingham cases from the METABRIC cohort (discovery set), 
and gene expression levels were compared between LVI positive and LVI negative 
cases. The LVI status for all patients was evaluated morphologically using 
hematoxylin and eosin (H&E) staining on full-face tumor sections. Besides, 
corresponding full-face tumor sections for each patient were stained 
immunohistochemically (IHC) with CD34 and D2-40 (podoplanin, PDPN), [10] to 
refine the status of LVI. Cases were considered LVI negative by the absence of LVI 
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in both H&E and IHC stained section. Cases with discordant results or showing 
lymph node positive but LVI negative were excluded to avoid bias caused by false 
positive or false negative diagnosis. 
A linear model for microarray data and RNA-seq package (LIMMA) method [11] was 
applied for detecting differentially expressed genes/transcripts between LVI positive 
and negative groups. This supervised approach of the differential gene expression 
analysis is compatible with the Affymetrix gene expression data. The Addenbrookes’ 
Hospital cases, within the METABRIC cohort (n=521), with defined LVI status were 
used to validate the results of the differential gene expression analyses externally. 
The top differentially expressed genes were ranked based on their p-value of 
association with LVI. Subsequently, the CNAs of the top differentially expressed 
genes were determined using the Affymetrix SNP6 Copy Number Inference Pipeline 
(Cancer Genomics Computation Analysis group of the Broad Institute, USA) [7]. 
Cytosolic factor Saccharomyces cerevisiae-like 1 (SEC14L1) was identified as one 
of the highly significant genes associated with LVI. The prognostic impact of 
SEC14L1 mRNA expression was evaluated in the 1980 cases of METABRIC cohort 
and externally validated using the Breast Cancer Gene-Expression Miner v4.0 
[n=5788] [12].  
Analysis of SEC14L1 protein expression  
The Nottingham BC series which were included in the METABRIC cohort were used 
in this study. All patients were treated without neoadjuvant treatment. ER, 
progesterone receptor (PR), HER2 and Ki67 were stained and scored according to 
guideline recommendations and as previously published (7, 8). The cut-off value of 
ER and PR were determined as 1% (9). ER-positive and HER2 negative tumors 
were considered as the luminal class with PR negative and high Ki67 (labelling index 
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< 10%) cases were determined as luminal B subtype. Clinicopathological data and 
patients’ outcome had been recorded and regularly updated. The recorded outcome 
data comprised survival status, mean survival in months, recurrence of disease 
(including distant metastases) and cause of death. BC-specific survival (BCSS) was 
determined as the time from the day of surgery until the time of death from or with 
BC in 10 years follow-up. 
Antigen binding specificity for rabbit polyclonal anti-SEC14L1 antibody (HPA028703, 
Sigma Aldrich, UK) was examined by western blotting (WB) at 1:500. A set of 
different cell lysates was utilized; MCF7, HeLa, MDA-MB-231, Jurkat, human 
embryonic kidney (HEK) 293, MDA-MB-468 (all obtained from the American Type 
Culture Collection; Rockville, MD, USA). 
Prior to assessment of SEC14L1 IHC expression on tissue microarray (TMA), a 
subset of full-face tissue sections of breast cancer (n=20) was IHC stained. IHC was 
performed on (4 μm) TMA sections using Novocastra Novolink Polymer Detection 
Systems kit (Code: RE7280-K, Leica Biosystems, UK) following the manufacturer’s 
protocol. Briefly, all full-face and TMA sections were incubated on a hot plate at 60˚C 
for 10 minutes; then deparaffinized in xylene and rehydrated through descending 
grades of ethanol.  SEC14L1 staining was performed utilizing anti-SEC14L1 primary 
antibody at 1:25 dilution in Leica Antibody Diluent, for 60 minutes. Finally, 3-3’ 
Diaminobenzidine tetrahydrochloride (Novolink DAB substrate buffer plus) was 
freshly prepared and used as a chromogen. Counterstaining was performed using 
Meyer’s hematoxylin for 6 min. Negative and positive controls (anti-human-β-2-
microglobulin; A0072, Dako) were included. The cytoplasmic expression of SEC14L1 
was assessed using the percentage of positivity (0-100%) and staining intensity 
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(Negative: Score 0, Weak: Score 1, Moderate: Score 2, and Strong: Score 3). H-
score of SEC14L1 was calculated as previous publication [16].  
This work was approved by Nottingham Research Ethics Committee 2 under the 
title: Development of molecular genetic classification of breast cancer. All tissue 
samples included in this study were from patients who were consented before 
inclusion in the study cohort. 
Statistical analysis 
Statistical analysis was performed using SPSS (IBM SPSS Statistics, Version 22). 
The relationship between SEC14L1 CNA and mRNA expression was calculated 
using analysis of variance (ANOVA) test with Bonferroni correction. Differences 
between two groups were assessed using Mann-Whitney test (non-normal 
distribution) to determine the associations between SEC14L1 mRNA expression and 
LVI status. Chi-square test was used to evaluate the relationship between SEC14L1 
expression and categorical variables. For dichotomization of the data, X-Tile (X-Tile 
Bioinformatics Software, Yale University, version 3.6.1) was used. Survival curves 
were generated by Kaplan-Meier survival analysis with differences in outcome 
assessed by Log Rank test. Cox’s proportional hazard method was performed for 
multivariate analysis to identify the independent prognostic/predictive factors. The p-
value ≤ 0.05 was considered significant. 
 
RESULTS 
There was a strong positive correlation between SEC14L1 mRNA expression and 
SEC14L1 gene copy number gain; higher levels of SEC14L1 mRNA were detected 
in cases with copy number gain compared to those with neural copy number 
(p<0.0001). SEC14L1 mRNA expression was significantly lower in the copy number 
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loss group (p<0.0001). Further analysis of SEC14L1 CNA revealed a significant 
association with histological grade 3 (p<0.0001) and luminal B molecular subtype 
(p<0.0001) (Table 1). The cut-off value of SEC14L1 mRNA expression was 
determined at median value. The overexpression of SEC14L1 mRNA was 
associated with the higher histological grade (p<0.0001), axillary node metastasis 
(p<0.0001) and the intrinsic molecular subtypes (p<0.0001; Table 1).  
In the METABRIC cohort, the survival of patients with SEC14L1 copy number gain 
was significantly shorter than those of copy number neutral group (p=0.0007). 
However, no difference of survival was observed between CNA loss and neutral 
groups (p=0.13) (Figure 1A). High expression of SEC14L1 mRNA conferred a 
significantly worse prognosis compared to low SEC14L1 mRNA expression 
(p=0.00049; Figure 1B). External validation of the prognostic power of SEC14L1 
mRNA expression in the Breast Cancer Gene-Expression Miner v4.0 revealed that 
high SEC14L1 mRNA expression was associated with poor prognosis (p<0.05).In 
the METABRIC cohort, the survival of patients with SEC14L1 copy number gain was 
significantly shorter than those of copy number neutral group (p=0.0007). However, 
no difference of survival was observed between CNA loss and neutral groups 
(p=0.13) (Figure 1A). High expression of SEC14L1 mRNA is relevant with a worse 
prognosis compared to low SEC14L1 mRNA expression (p=0.00049; Figure 1B). 
External validation of the prognostic power of SEC14L1 mRNA expression in the 
Breast Cancer Gene-Expression Miner v4.0 revealed that high SEC14L1 mRNA 
expression was associated with adverse prognosis (p<0.05). 
SEC14L1 protein expression 
Evaluation of WB supported a specific binding affinity of the anti-SEC14L1 primary 
antibody to single protein bands for each cell lysate around the predicted molecular 
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mass (77 kilo Dalton) of SEC14L1 protein, confirming the specificity of the antibody 
(Supplementary Figure 1). On full-face tissue sections, strong protein expression of 
SEC14L1 was detected in the cytoplasm of breast cancer cells (Figure 2). On the 
other hand, weaker protein expression was observed in the adjacent normal 
epithelial tissue. Assessment of full-face sections revealed a homogeneous 
expression pattern for SEC14L1 protein confirming the reliability of TMA to detect its 
expression (Figure 3). The optimal cut-off value of SEC14L1 protein expression was 
determined at H score of 80. At this cut-off, 70 % cases showed low/negative 
cytoplasmic expression whereas positive/high cytoplasmic expression was detected 
in 30%.  
There was an association between SEC14L1 protein expression and LVI status 
(p<0.0001) and other variables of poor prognosis (Table 2). SEC14L1 expression 
was associated with a higher histological grade (p=0.011), HER2 positivity 
(p=0.004), and luminal B subtype (p=0.006). Outcome analysis revealed a positive 
association between SEC14L1 protein expression and shorter survival (p=0.0008; 
Figure 1C). In univariate analysis, SEC14L1 protein expression (p=0.001), 
histological grade (p<0.0001), LVI status (p=0.002), tumor size (p=0.005) and nodal 
status (p=0.013) were all significant predictors of outcome. Multivariate analysis 
including prognostic variables significant in univariate analysis SEC14L1 protein 
expression was an independent prognostic variable of survival (p=0.019; Table 3). 
 
DISCUSSION  
In the present research, we have tried to decipher the molecular mechanism 
underlying LVI in BC. High throughput molecular techniques coupled with 
bioinformatics and strict definition of LVI status were utilized to identify genes 
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associated with LVI that can potentially be used as therapeutic targets. Following 
internal and external validation, SEC14L1 was identified as one of the top 
differentially expressed genes associated with LVI and also with prognosis. Further 
examination of SEC14L1 at protein expression level confirmed its association with 
LVI and indicated its independent prognostic value in BC. 
SEC14L1 gene is located within a discrete region of 17q25 that frequently shows 
copy number alterations in BC [17]. A proximate locus, the17q23 locus is well 
documented in BC, and the key feature of this amplified locus is its oncogenic 
activity in BC both in vitro and in vivo [18]. In this study, there was an association not 
only between SEC14L1 CNA and mRNA expression but also between CNA and 
mRNA expression and LVI status.  In a recent investigation of prostatic carcinoma, a 
prognostic 12-gene signature associated with criteria of aggressive clinical outcome 
included SEC14L1, also confirmed by real-time quantitative RT-PCR and 
immunohistochemistry assays [19]. SEC14L1 cytoplasmic protein overexpression 
was frequently found in the Transmembrane Protease, Serine 2 (TMPRSS2)/ Ets-
related gene (ERG) fusion-positive prostate cancer, and the clinical and prognostic 
power of SEC14L1 strongly depends on this fusion status in prostate cancer [21].  
SEC14 like proteins have been implicated in hepatocellular carcinomas [20]. 
TMPRSS2/ERG fusion has been revealed to be associated with several molecular 
alterations including deletion of the phosphatase and tensin homolog gene (PTEN) 
[22]. Several previous studies suggested that PTEN loss is strongly correlated with 
transcriptional instability and was associated with poor outcome of HER2 positive BC 
[23, 24]. TMPRSS2/ERG fusion was also thought to be correlated with androgen 
receptor activity [25], transcriptional stability [26], and stem cell maintenance [27] in 
cancer. These mechanisms have essential roles in cell proliferation, adhesion, 
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invasion and migration. Thus, SEC14L1 may play a pivotal role in the regulation of 
cell growth/tissue development and cell adhesion, underlying LVI and metastasis in 
breast cancer. 
Moreover, this study has revealed that SEC14L1 protein expression had a significant 
relationship with HER2 status and high histological grade. We previously found that 
definite LVI was significantly correlated with HER2 positivity [1] and tumor 
microenvironment plays a crucial role in the HER2 signaling pathway, invasion and 
metastasis including the development of LVI [28, 29]. A previous study suggested 
that SEC14L1 might play an important role in trafficking proteins on cellar membrane 
[30]. SEC14L1 belongs to SEC14 cytosolic factor family that plays a role in the 
intracellular transport system [31] and innate immunity [32]. SEC14L1 
overexpression may be responsible for enhanced intra-tumor signaling pathways 
including HER2 and influence the tumor microenvironment to promote tumor growth, 
promoting LVI and metastasis in BC. Although SEC14L1 was associated with higher 
histological grade, the association with outcome was independent of grade. In this 
study, SEC14L1 was associated with lymph node metastasis at mRNA levels, and its 
expression at mRNA and protein levels was associated with outcome independent of 
other prognostic variables. 
In conclusion, this study revealed and confirmed that SEC14L1 expression is a 
significant prognostic factor of BC. Over-expression of SEC14L1 plays a crucial role 
in the development of LVI, BC progression and metastasis. Further functional 
assessment of SEC14L1 to determine its therapeutic value in BC is warranted. 
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Figure Legends 
 
Figure 1: Kaplan-Meier survival plots showing the association between SEC14L1 
copy numbers (A), mRNA expression (B) and SEC14L1 protein expression (C) and 
outcome. 
 
Figure 2: SEC14L1 protein expression in normal and breast cancer tissue. 
Cytoplasmic SEC14L1 expression was overexpressed in breast cancer cells 
compared to the expression in epithelial cells of normal duct lobular units (Black 
arrow: invasive carcinoma and white arrow: normal mammary gland).  
 
Figure 3: Immunohistochemistry expression of SEC14L1 in tissue microarray 
images.  
SEC14L1 expression of the cytoplasm in cancer cells was distributed as follows; a) 
No staining, b) weak staining, c) moderate staining, and d) strong staining. 
 
 
 



Table 1: Association between SEC14L1 copy number alterations and SEC14L1 mRNA expression and clinicopathological parameters in the METABRIC cohort 
of invasive breast cancer (n=1980) 
 
Factors 
Expression of SEC14L1 (copy number alterations) Expression of SEC4L1 (mRNA) 
Loss  Neutral  Gain Total p-value > Median < Median Total p-value 
Tumour size 
> 2cm 30 (2.2%) 1114 (83.3%) 193 (14.4%) 1337 
0.063 
657 (49.1%) 681 (50.9%) 1338 
0.10 
< 2cm 13 (2.1%) 536 (87.3%) 65 (10.6%) 614 327 (53.1%) 289 (46.9%) 616 
Nodal status 
Positive 20 (2.1%) 787 (84.1%) 129 (13.8%) 936 
0.76 
413 (44.0%) 525 (56.0%) 938 
<0.0001 
Negative 23 (2.2%) 880 (85.1%) 131 (12.7%) 1034 575 (55.6%) 460 (44.4%) 1035 
Histological grade 
Grade 3 22 (2.3%) 764 (80.3%) 165 (17.4%) 951 
<0.0001 
355 (37.3%) 597 (62.7%) 952 
<0.0001 
Grade 1, 2 21 (2.2%) 834 (88.9%) 83 (8.8%) 938 589 (62.7%) 351 (37.3%) 940 
Molecular subtypes 
Luminal A 14 (2.0%) 651 (90.8%) 52 (7.3%) 717 
<0.0001 
481 (67.0%) 237 (33.0%) 718 
<0.0001 
Luminal B 15 (3.1%) 358 (73.4%) 115 (23.6%) 488 252 (51.6%) 236 (48.4%) 488 
HER2 enriched 5 (2.1%) 201 (84.1%) 33 (13.8%) 239 78 (32.5%) 162 (67.5%) 240 
Basal-like 5 (1.5%) 275 (83.8%) 48 (14.6%) 328 74 (22.5%) 255 (77.5%) 329 
Normal-like 4 (2.0%) 183 (92.0%) 12 (6.0%) 199 101 (50.8%) 98 (49.2%) 199 
 
Table 2: Association between SEC14L1 protein expression and the clinicopathological factors 
 
Factors 
Expression of SEC14L1 
Low High Total p-value 
Tumor size 
> 2cm 68 (68.7%) 31 (31.3%) 99 
0.75 
< 2cm 49 (71.0%) 20 (29.0%) 69 
Nodal status 
Positive 55 (67.1%) 27 (32.9%) 82 
0.48 
Negative 62 (72.1%) 24 (27.9%) 86 
Histological grade 
Grade 3 53 (60.9%) 34 (39.1%) 87 
0.011 
Grade 1, 2 64 (79.0%) 17 (21.0%) 81 
Lymphovascular invasion 
Positive 43 (51.8%) 40 (48.2%) 83 
<0.0001 
Negative 74 (88.1%) 10 (11.9%) 84 
Estrogen receptor 
Positive 85 (69.1%) 38 (30.9%) 123 
0.80 
Negative 32 (71.1%) 13 (28.9%) 45 
Progesterone receptor 
Positive 66 (70.2%) 28 (29.8%) 94 
0.96 
Negative 44 (69.8%) 19 (30.2%) 63 
HER2 
Positive 14 (53.8%) 12 (46.2%) 26 
0.036 
Negative 98 (74.2%) 34 (25.8%) 132 
Molecular subtypes 
Luminal A-like 30 (88.2%) 4 (11.8%) 34 
0.006 
Luminal B-like 39 (65.0%) 21 (35.0%) 60 
HER2-positive 14 (53.8%) 12 (46.2%) 26 
Triple negative 23 (85.2%) 4 (14.8%) 27 
Abbreviations: ER, Estrogen receptor; PgR, Progesterone receptor 
 
Table 3: Univariate and multivariate survival analysis of clinicopathological factors and SEC14L1 protein 
expression in breast cancer 
 
Factors 
Univariate analysis  Multivariate analysis 
Hazard 
Ratio 95% CI p-value 
Hazard 
Ratio 95% CI p-value 
SEC14L1    
Low Reference Reference 
High 2.5 1.43-4.21 0.001 2.0 1.12-3.54 0.019 
Lymphovascular 
invasion 
Negative Reference Reference 
Positive 2.5 1.41-4.47 0.002 1.5 0.79-2.74 0.22 
Tumor size 
< 2cm Reference Reference 
> 2cm 2.4 1.30-4.43 0.005 1.8 0.96-3.47 0.067 
Nodal status 
Negative Reference Reference 
Positive 2.0 1.16-3.53 0.013 1.4 0.76-2.47 0.29 
Histological grade 
Grade1-2 Reference Reference 
Grade 3 3.7 1.96-6.87 <0.0001 2.7 1.41-5.15 0.003 
 
 
 
 
